Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Prelude Therapeutics will webcast a September 16 fireside chat from the H.C. Wainwright Global Investment Conference, with replay access for 90 days.

Rhea-AI Summary

Prelude Therapeutics (PRLD) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York City, held September 14-16, 2026. On September 16, 2026, at 10:30 a.m. ET, members of the executive team will join a fireside chat. A live webcast and a 90-day archive of the session will be available on the company’s website under Events and Presentations.

Key Figures

Conference dates: September 14-16, 2026

Conference dates

September 14-16, 2026

H.C. Wainwright 28th Annual Global Investment Conference

Key Terms

precision oncology, kat6a degraders, jak2v617f mutant selective inhibitors, targeted protein degradation, +1 more

5 terms

precision oncology medical

"a clinical-stage precision oncology company"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

kat6a degraders technical

"Our pipeline features highly selective KAT6A degraders"

KAT6A degraders are drug candidates that bind the KAT6A protein—a cellular enzyme that helps switch genes on—and mark it for destruction by the cell’s natural recycling machinery. For investors, they matter because removing a problematic protein can be a more decisive way to stop disease processes (think pulling a broken part out of a machine rather than just turning it off), which can translate into new treatments, clinical trial value, and potential commercial upside if safety and effectiveness are proven.

jak2v617f mutant selective inhibitors medical

"and JAK2V617F mutant selective inhibitors"

A class of drugs that specifically block the activity of the JAK2 protein carrying the V617F mutation, a faulty switch that drives abnormal blood cell growth in certain blood cancers. By targeting the mutant form while sparing the normal protein, these inhibitors aim to control disease with fewer side effects—like fixing a single bad fuse instead of shutting down the whole circuit. For investors, they matter because successful development or approval can change treatment standards and create substantial commercial and clinical value.

targeted protein degradation technical

"leveraging our expertise in targeted protein degradation"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

degrader antibody conjugates technical

"next generation degrader antibody conjugates (DACs)"

Degrader antibody conjugates are lab-made antibodies attached to molecules that prompt a cell to break down a specific protein in or on the cell. Think of the antibody as a GPS guiding a demolition crew (the attached molecule) to a single building (the target protein), which can shut down a disease process more precisely than traditional drugs; investors watch them because successful degrader conjugates can create novel, potentially more effective therapies with distinct clinical and commercial value, but they also carry typical development and regulatory risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the H.C. Wainwright 28^th Annual Global Investment Conference, taking place in New York City September 14-16, 2026.

On Wednesday, September 16, 2026, at 10:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Charles Morris, MBChB, MRCP. Chief Medical Officer, Peggy Scherle, Ph.D., Chief Scientific Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.

About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and JAK2V617F mutant selective inhibitors -- new approaches to clinically validated targets with transformative potential for patients. We are leveraging our expertise in targeted protein degradation to create and develop next generation degrader antibody conjugates (DACs) with novel payloads. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.

Investor Contact: 
Robert Doody
Senior Vice President, Investor Relations 
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com

FAQ

How can investors access the Prelude Therapeutics fireside chat at the H.C. Wainwright conference?

A live webcast of the September 16, 2026 fireside chat at 10:30 a.m. ET can be accessed on Prelude Therapeutics’ website under the Events and Presentations section.

How long will the recording of the Prelude Therapeutics fireside chat be available?

The company states that the recording of the fireside chat will be archived and available on its website for 90 days.